ANTA Sports to Acquire 29% Stake in PUMA, Further Strengthening Globalization Strategy
27.1.2026 01:17:00 CET | Business Wire | Press Release
ANTA Sports Products Limited (“ANTA Sports” or the “Company,” stock codes: 2020 (HKD counter) and 82020 (RMB counter), and its subsidiaries collectively the “Group”), today announced it has reached a share purchase agreement with Groupe Artémis, the investment company of the Pinault family, to acquire a 29.06% stake in PUMA SE, the company behind iconic global sports brand PUMA. The stake is valued at EUR 1.5 billion in cash. The transaction marks a significant step in ANTA Sports’ globalization strategy, further enhancing its reach, recognition and competitiveness in the global sporting goods market.
The transaction is expected to close by the end of 2026, subject to relevant regulatory approvals and customary closing conditions. The equity acquisition will be entirely financed with ANTA Sports’ internal cash resources.
Ding Shizhong, Board Chairman of ANTA Sports, commented: “This acquisition makes ANTA Sports the largest shareholder of PUMA and marks a major step forward in our ‘single-focus, multi-brand, globalization’ strategy. PUMA is an iconic global brand with substantial heritage. Working with PUMA, we look forward to learning from each other and joining hands to fully unlock the brand’s full potential. This will further accelerate ANTA Sports’ globalization, and help drive the next chapter of growth for the global sports markets including China – creating lasting value for both companies’ consumers and shareholders worldwide.”
ANTA Sports has over 35 years of experience in the sporting goods industry. Building on its foundation and growth engine in the Chinese market, it has achieved an industry-leading position in the country. The Group has been expanding operations across key markets including Southeast Asia, the Middle East, Africa, North America, and Europe. It has successfully empowered multiple international brands, accumulating extensive experience in multi-brand operations management and brand value revitalization, including its unique “Brand + Retail” business model with a proven track record.
PUMA is globally renowned for its rich heritage and has built deep brand equity and worldwide presence. It also brings powerful sports assets – particularly in football, running, training, basketball, and motorsport, and has a wide reach across key sports markets including Europe, Latin America, Africa, and India. Anta Sports’ portfolio brands and PUMA offer highly complementary strengths across product portfolio, category specialization and regional footprint.
Commenting on the strategic rationale of the transaction, Mr. Ding emphasized: “ANTA has always admired PUMA’s long-term brand value and potential. Such strong brand DNA and value heritage are rare to come by. We believe PUMA’s share price over the past few months does not fully reflect the long-term potential of the brand. We have confidence in its management team and strategic transformation. Moving forward, we hope to build strong trust, work together at arm’s length, and leverage our complementary strengths without comprising independence. We look forward to supporting the brand’s ongoing revival.”
ANTA Sports fully appreciates PUMA’s management culture and independent governance as a German-listed company. ANTA Sports intends to seek adequate representation on PUMA’s Supervisory Board. These representatives will work closely with the other Supervisory Board members from both the shareholders’ and employee representatives’ side, while preserving PUMA’s strong brand identity and heritage. The Group will carefully assess the possibility of further deepening the partnership between the two parties in the future. The Group currently has no plans to make a takeover offer for PUMA.
About ANTA
ANTA was established in 1991; while ANTA Sports Products Limited, a widely recognized global sportswear company, was listed on the Main Board of HKEx in 2007 (Stock Codes: 2020 (HKD counter) and 82020 (RMB counter)). The mission of the Company is to bring the transcendent sports spirit into everyone’s life. ANTA Sports principally engages in R&D, design, manufacturing, marketing and sales of professional sports products including footwear, apparel and accessories. By embracing an all-round brand portfolio including ANTA, FILA, DESCENTE, KOLON SPORT, MAIA ACTIVE and JACK WOLFSKIN, etc., ANTA Sports aims to unlock the potential of both the mass and high-end sportswear markets. ANTA Sports is also the largest shareholder of Amer Sports, Inc., a global group of iconic sports and outdoor brands, including Arc’teryx, Salomon, Wilson, Peak Performance, and Atomic, whose shares are listed on the New York Stock Exchange (NYSE: AS).
Official website: http://ir.anta.com
About PUMA
PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For more than 75 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 20,000 people worldwide, and is headquartered in Herzogenaurach/Germany.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260126085622/en/
Contacts
For further information, please contact:
Investor Contact
ANTA Sports Products Limited
Investor Relations Department
Tel: (852) 2116 1660
Fax: (852) 2116 1590
E-mail: ir@anta.com.hk
Media Contact
FGS Global
Claudia Kosser, Germany/Europe, +49 162 2737953, Claudia.Kosser@fgsglobal.com
Danielle Berg, US/international, +1 214 7092300, Danielle.Berg@fgsglobal.com
Louis Hung, APAC, +852 90841801, Louis.Hung@fgsglobal.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom